Skip to main content
. 2022 May 30;20:197. doi: 10.1186/s12916-022-02387-0

Fig. 2.

Fig. 2

CSF cfDNA documents molecular characterization of EGFR-mutated NSCLC with LM. A Frequency of shared versus CSF-private or plasma-private alterations in paired CSF-plasma samples. B Discordance of on-target and off-target resistant mechanisms to osimertinib upon LM progression between paired CSF and plasma. CSF, cerebrospinal fluid; amp, amplification; mut, mutation